This article is more than 5 years old. Information may no longer be current.
Predictors for sustained clinical remission to abatacept different based on age
Click Here to Manage Email Alerts
Abatacept showed effectiveness in treating older and younger patients with rheumatoid arthritis, but baseline characteristics correlated with sustained clinical remission were different among the age groups, according to study investigators.
Researchers prospectively identified 277 biologic-naive patients with rheumatoid arthritis who were treated with IV abatacept (Orencia, Bristol-Myers Squibb) and assessed for 48 weeks in 43 hospitals and rheumatology clinics in Japan. The 28-joint disease activity score with C-reactive protein (DAS29-CRP) was used to determine predictive factors correlated with sustained clinical remission in patients aged at least 65 years between 24 and 48 weeks, and logistic regression was used in younger patients.
Results showed, at 24 weeks, 35.1% of older patients achieved clinical remission and 36.5% achieved clinical remission at 48 weeks. Clinical remission at 24 weeks was achieved by 34.9% of young patients and in 43.4% at 48 weeks. Investigators noted clinical remission was significantly correlated with anti-citrullinated protein antibody (ACPA) positivity and a lower DAS28-CRP score, although a lower health assessment questionnaire–disability index (HAQ-DI) score was not.
According to researchers, DAS28-CRP and HAQ-DI were predictors for sustained clinical remission in younger patients, but ACPA was not considered useful for the prediction of sustained clinical remission. ‒ by Monica Jaramillo
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts